Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2023-11-14 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
112年第3季財務報告書 — 202303_1795_AI1.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "合併財務報告暨會計師核閱報告" which translates to "Consolidated Financial Report and Accountant's Review Report". It covers financial statements such as consolidated balance sheets, income statements, statements of changes in equity, and cash flow statements for the third quarter of the years 112 and 111 (Taiwanese calendar years, corresponding roughly to 2023 and 2022). The document includes detailed financial data, notes on accounting policies, and an accountant's review report (核閱報告). The presence of detailed financial statements and notes, along with the accountant's review, indicates this is an interim or quarterly financial report rather than a full annual report. The reference to "國際會計準則第三十四號「期中財務報導」" (IAS 34 Interim Financial Reporting) confirms this is an interim report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2023
2023-11-14 Chinese
112年第3季財務報告書 — 202302_1795_AIA.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements With Independent Auditors’ Review Report For the Six Months Ended June 30, 2023 and 2022' for Lotus Pharmaceutical Co., Ltd. It includes detailed consolidated balance sheets, statements of comprehensive income, changes in equity, cash flows, and notes to the consolidated financial statements. The presence of an Independent Auditors’ Review Report indicates this is a review of interim financial information, specifically for a six-month period ending June 30, 2023. The document references International Accounting Standard 34, 'Interim Financial Reporting', and the Financial Supervisory Commission of the Republic of China, confirming it is an interim report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, meeting the criteria for an Interim / Quarterly Report (IR). It is not a full annual report (10-K), nor is it merely an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-11-14 Chinese
112年第3季財務報告書 — 202302_1795_AI1.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "合併財務報告暨會計師核閱報告" which translates to "Consolidated Financial Report and Accountant's Review Report". It covers the periods of the second quarter of the years 民國112 and 111 (which correspond to 2023 and 2022). The content includes consolidated balance sheets, income statements, statements of changes in equity, cash flow statements, and detailed notes on accounting policies and other disclosures. The presence of an accountant's review report (核閱報告) indicates this is a reviewed interim financial report rather than a full annual report. The document is comprehensive and contains actual financial data and analysis for a period shorter than a full fiscal year (half-year). Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2023
2023-11-14 Chinese
112年第3季財務報告書 — 202301_1795_AIA.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements With Independent Auditors’ Review Report For the Three Months Ended March 31, 2023 and 2022' for Lotus Pharmaceutical Co., Ltd. It includes detailed consolidated balance sheets, statements of comprehensive income, changes in equity, cash flows, and notes. The auditor's report is a review report (not a full audit) in accordance with International Accounting Standard 34, which governs interim financial reporting. The period covered is three months, indicating this is a quarterly or interim report. The document contains substantive financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-11-14 Chinese
112年第3季財務報告書 — 202301_1795_AI1.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a consolidated financial report for the first quarter of the years 112 and 111 (Taiwanese calendar years), including a review report by an accounting firm. It contains detailed financial statements such as consolidated balance sheets, income statements, statements of changes in equity, and cash flow statements, along with extensive notes on accounting policies, related party transactions, and other disclosures. The document explicitly states it is a "合併財務報告暨會計師核閱報告" (Consolidated Financial Report and Accountant's Review Report) and mentions it is prepared under the International Accounting Standard 34 for interim financial reporting. The presence of quarterly financial data and the nature of the report indicate it is an Interim / Quarterly Report. It is not a full annual report (10-K) as it covers only a quarter and is reviewed, not audited. It is not merely an audit report or certification, but a full financial report with substantive financial data and analysis for a period shorter than a fiscal year. Therefore, the correct classification is Interim / Quarterly Report (IR). The document length and content confirm it is not a mere announcement or certification, so it is not RPA or RNS. Q1 2023
2023-11-14 Chinese
112年11月法人說明會簡報 — 179520231114E002.pdf
Investor Presentation Classification · 100% confidence The document is titled '2023 Q3 EARNINGS RESULTS Investor Presentation' and contains detailed financial results for the third quarter of 2023, including revenue, gross profit, net income, EPS, and business highlights. It also includes business outlook, pipeline updates, and strategic information. The content is structured as a presentation with slides and charts, typical of an investor presentation. The document length is about 14,788 characters, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full quarterly report (IR) with comprehensive financial statements, nor is it a simple earnings release (ER) which would be shorter and less detailed. The presence of forward-looking statements, business highlights, financial results, and strategic outlook aligns with the definition of an Investor Presentation (IP). Therefore, the correct classification is Investor Presentation (IP).
2023-11-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.